Ocular Therapeutix (OCUL) Tops Q1 EPS by 4c; Sees DEXTENZA NDA Submission in H215

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. CSX
7. LRCX
8. MRK
9. LVS
10. SAP

Go back to Ocular Therapeutix (OCUL) Tops Q1 EPS by 4c; Sees DEXTENZA NDA Submission in H215

Ocular TherapeutixTM Announces Plans to Proceed with an NDA Submission for OTX-DP for Treatment of Post-Surgical Ocular Pain Indication; Reports First Quarter 2015 Financial Results

May 15, 2015 6:45 AM EDT

Company Provides Updates on Anticipated Clinical Milestones and Development Plans

Conference Call Today at 8:00 am Eastern Time

BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the first quarter ended March 31, 2015 and provided an update on its clinical and preclinical programs for its proprietary hydrogel platform technology. Following a meeting with the Food and Drug Administration... More